Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia

Immunology

Volumn 90, Issue 1, 1997, Pages 95-100

  Szabo C ^a   Hasko G ^b   Zingarelli, B ^a   Nemeth Z H ^b   Salzman, A L ^a   Kvetan, V ^c   Pastores, S Mccarthy ^c   Vizi, E S ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; INTERLEUKIN 10; INTERLEUKIN 6; ISOPRENALINE; LIPOPOLYSACCHARIDE; N(G) METHYLARGININE; NITRIC OXIDE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; COMPLICATION; CONTROLLED STUDY; DRUG THERAPY; ENDOTOXEMIA; HEMODYNAMICS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASODILATATION;

EID: 0031022127     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1997.00137.x     Document Type: Article

References (34)

1. SCHLAG G. & REDL H. (eds.) (1993) Pathophysiology of Shock, Sepsis and Organ Failure. Springer-Verlag, Berlin.
2. SZABÓ C. (1995) Alterations in nitric oxide production in various forms of circulatory shock. New Horizons 3, 2.
3. SZABÓ C. (1996) The role of peroxynitrite in the pathophysiology of shock and inflammation. Shock 6, 79.
4. PETROS A., LAMB G., LEONE A., MONCADA S., BENNETT D. & VALLANCE P. (1994) Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28, 34.
5. RUDIS M.L., BASHA M.A. & ZAROWITZ B.J. (1996) Is it time to reposition vasopressors and inotropes in sepsis? Critical Care Med 24, 525.
6. IGNATOWSKI T.A. & SPENGLER R.N. (1995) Regulation of macrophage-derived tumor necrosis factor production by modification of adrenergic receptor sensitivity. J Neuroimmunol 61, 61.
7. HASKÓ G., ELENKOV L.J., KVETAN V. & VIZI E.S. (1995) Differential effect of selective block of alpha-2 adrenoceptors on plasma levels of tumour necrosis factor-alpha, interleukin-6 and corticosterone induced by bacterial lipopolysaccharide in mice. J Endocrinol 144, 457.
8. SEVERN A., RAPSON N.T., HUNTFR C.A. & LIEW F.Y. (1992) Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J Immunol 148, 3441.
9. ELENKOV I.J., HASKÓ G., KOVACS K. & VIZI E.S. (1995) Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by selective alpha- and beta-adrenergic drugs in mice. J Neuroimmunol 61, 123.
10. HASKÓ G., SZABÓ C., MERKEL K. et al. (1996) Modulation of lipopolysaccharide-induced tumor necrosis factor and nitric oxide production by dopamine receptor agonists and antagonists in mice. Immunology Lett 49, 143.
11. BOUMA M.G., STAD R.K., VAN DEN WILDENBERG H.A. & BUURMAN W.A. (1994) Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 153, 4159.
12. PARMELY M.J., ZHOU W.W., EDWARDS C.K., BORCHERDING D.R., SILVERSTEIN R. & MORRISON D.C. (1993) Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 151, 389.
13. HASKÓ G., SZABO C., NÉMETH Z.H., KVETAN V., PASTORES S.M. & VIZI E.S. (1996) Adenosine receptor agonists differentially regulate IL-10 and TNF production in endotoxemic mice. J Immunol 157, 4634.
14. SZABÓ C, SALZMAN A.L. & ISCHIROPOULOS H. (1995) Peroxynitrite-mediated oxidation of dihydrorhodamine 123 occurs in early stages of endotoxic and hemorrhagic shock and ischemiareperfusion injury. FEBS Lett 372, 229.
15. SOUTHAN G.J., ZINGARELLI B., O'CONNOR M., SALZMAN A.L. & SZABO C. (1996) Spontaneous rearrangement of aminoalkylguanidines into mercaptoalkylguanidines - a novel class of nitric oxide synthase inhibitors with selectivity towards the inducible isoform. Br J Pharmacol 117, 619.
16. Wu C.C., SZABO C., CHEN S.J., THIEMERMANN C. & VANE J.R. (1994) Activation of soluble guanylyl cyclase by a factor other than nitric oxide or carbon monoxide contributes to the vascular hyporeactivity to vasoconstrictor agents in the aorta of rats treated with endotoxin. Biochem Biophys Res Comm 201, 436.
17. ZINGARELLI B., O'CONNOR M., WONG H., SALZMAN A.L. & SZABO C. (1996) Peroxynitrite-mediated DNA strand breakage activates poly-ADP ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. J Immunol 156, 350.
18. WISH W.C., COOK J.A. & HALUSHKA P.V. (1983) Arachidonic acid metabolism in endotoxin tolerance. Adv Shock Res 10, 131.
19. NELSON H.S. (1982) Beta-adrenergic agonists. Chest 82, 33S.
20. 2. J Exp Med 180, 2365.
21. VAN DER POLL T., COYLE S.M., BARBOSA K., BRAXTON C.C. & LOWRY S.F. (1996) Epinephrine inhibits tumor necrosis factor- and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 97, 713.
22. 2. J Exp Med 180, 2365.
23. PLATZER C., MEISEL CH., VOGT K., PLATZER M. & VOLK H.-D. (1994) Up-regulation of monocytic IL-10 by tumor necrosis factor- and cAMP elevating drugs. Int Immunol 7, 517.
24. ARAI T., HIROMATSU K., KOBAYASHI N. et al. (1995) IL-10 is involved in the protective effect of dibutyryl cyclic adenosine monophosphate on endotoxin-induced inflammatory liver injury. J Immunol 155, 5743.
25. THIEMERMANN C., WU C.C., SZABÓ C., PERRETTI M. & VANE J.R. (1993) Tumour necrosis factor is an endogenous mediator of the induction of nitric oxide synthase in endotoxin shock in the rat. Br J Pharmacol 110, 177.
26. SZABÓ C., Wu C.C., MITCHELL J.A., GROSS S.S., THIEMERMANN C. & VANE J.R. (1993) Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res 73, 991.
27. FONTEH A.N., WINKLER J.D., TORPHY T.J., HERAVI J., UNDEM B.J. & CHILTON F.H. (1993) Influence of isoproterenol and phosphodiesterase inhibitors on platelet-activating factor biosynthesis in the human neutrophil. J Immunol 151, 339.
28. BULUT V., SEVERN A. & LIEW F.Y. (1993) Nitric oxide production by murine macrophages is inhibited by prolonged elevation of cyclic AMP. Biochem Biophys Res Comm 195, 1134.
29. FEINSTEIN D.L., GALEA E. & REIS D.J. (1993) Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. J Neurochem 60, 1945.
30. KOIDE M., KAWAHARA Y., NAKAYAMA I., TSUDA T. & YOKOYAMA M. (1993) Cyclic AMP-elevating agents induce an inducible type of nitric oxide synthase in cultured vascular smooth muscle cells. Synergism with the induction elicited by inflammatory cytokines. J Biol Chem 268, 24959.
31. IMAI T., HIRATA Y., KANNO K. & MARUMO F. (1994) Induction of nitric oxide synthase by cyclic AMP in rat vascular smooth muscle cells. Clin Invest 93, 543.
32. WORTHLEY L.I., TYLER P. & MORAN J.L. (1985) A comparison of dopamine, dobutamine and isoproterenol in the treatment of shock. Int Care Med 11, 13.
33. G-methyl-L-arginine. an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs. Critical Care Med 22, 1835.
34. PASTORES S.M., HASKÓ G., VIZI E.S. & KVETAN V. (1996) The role of vasoactive drugs in the regulation of cytokine production in sepsis. New Horizons 4, 252.